Viatris Inc VTRS
Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.
Viatris' executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules, and what we believe is industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise. Viatris' portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.25B | $14.69B | $15.39B | $16.22B | $17.81B | $11.82B | $11.37B | $11.27B | — |
| Cost of revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B | $8.15B | $7.60B | $7.43B | — |
| Gross profit | $5.01B | $5.62B | $6.44B | $6.50B | $5.58B | $3.80B | $3.90B | $4.00B | — |
| R&D | — | — | — | — | $751.1M | $555.1M | $639.9M | $704.5M | — |
| SG&A | $3.79B | $4.10B | $4.07B | $4.18B | $4.53B | $3.34B | $2.56B | $2.44B | — |
| Total operating expenses | $7.68B | $5.61B | $5.67B | $4.88B | $5.61B | $4.01B | $3.18B | $3.10B | — |
| Operating income | -$2.66B | $10.1M | $766.2M | $1.61B | -$34.0M | -$210.8M | $715.5M | $905.6M | — |
| Interest expense | $471.3M | $550.0M | $573.1M | $592.4M | $636.2M | $497.8M | $517.3M | $542.3M | — |
| Pre-tax income | -$3.67B | -$623.2M | $202.9M | $2.81B | -$664.4M | -$721.2M | $154.4M | $298.4M | — |
| Income tax | $150.1M | $11.0M | $148.2M | $734.6M | $604.7M | $51.3M | $137.6M | $54.1M | — |
| Net income | -$3.51B | -$634.2M | $54.7M | $2.08B | -$1.27B | -$669.9M | $16.8M | $352.5M | — |
| EPS, basic | -3.00 | -0.53 | 0.05 | 1.71 | -1.05 | -1.11 | 0.03 | 0.69 | — |
| EPS, diluted | -3.00 | -0.53 | 0.05 | 1.71 | -1.05 | -1.11 | 0.03 | 0.68 | — |
| Shares, diluted (wtd. avg.) | — | — | $1.21B | $1.22B | $1.21B | $601.2M | $516.5M | $516.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.32B | $734.8M | $991.9M | $1.26B | $706.2M | $850.0M | $491.1M | $389.3M | $369.9M |
| Short-term investments | $40.7M | $38.0M | $37.0M | $35.3M | $38.2M | $39.1M | — | — | — |
| Receivables | $3.03B | $3.22B | $3.70B | $3.81B | $4.27B | $4.84B | $3.06B | — | — |
| Inventory | $4.00B | $3.85B | $3.47B | $3.52B | $3.98B | $5.47B | $2.67B | — | — |
| Total current assets | $9.79B | $9.52B | $12.98B | $10.64B | $10.90B | $12.87B | $6.76B | — | — |
| Property, plant and equipment | $2.61B | $2.67B | $2.76B | $3.02B | $3.19B | $3.46B | $2.15B | — | — |
| Goodwill | $6.75B | $9.13B | $9.87B | $10.43B | $12.11B | $12.35B | $9.59B | $9.75B | — |
| Other intangibles | $15.10B | $17.07B | $19.18B | $22.61B | $26.13B | $29.68B | $11.65B | — | — |
| Total assets | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | — | — |
| Short-term debt | $1.93B | $8.3M | $1.94B | $1.26B | $1.88B | $2.31B | $1.51B | — | — |
| Total current liabilities | $7.09B | $5.78B | $7.78B | $6.75B | $9.88B | $10.56B | $5.57B | — | — |
| Long-term debt | $12.48B | $14.04B | $16.19B | $18.02B | $19.72B | $22.43B | $11.21B | — | — |
| Total liabilities | $22.48B | $22.87B | $27.22B | $28.95B | $34.35B | $38.60B | $19.37B | — | — |
| Retained earnings | -$388.3M | $3.42B | $4.64B | $5.18B | $3.69B | $5.36B | $6.03B | — | — |
| Total equity | $14.71B | $18.64B | $20.47B | $21.07B | $20.49B | $22.95B | $11.88B | $12.17B | $13.31B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.32B | $2.30B | $2.90B | $3.00B | $3.02B | $1.23B | $1.80B | $2.34B | — |
| Depreciation and amortisation | $2.80B | $2.89B | $2.74B | $3.03B | $4.51B | $2.22B | $2.02B | $2.11B | — |
| Stock-based compensation | $177.7M | $146.1M | $180.7M | $116.4M | $111.2M | $79.2M | $56.8M | -$3.3M | — |
| Capital expenditure | $378.8M | $326.0M | $377.0M | $406.0M | $457.2M | $243.0M | $213.2M | $252.1M | — |
| Investing cash flow | -$427.7M | $1.80B | -$864.5M | $1.47B | -$117.8M | -$301.1M | -$525.4M | -$1.21B | — |
| Financing cash flow | -$1.29B | -$4.33B | -$2.30B | -$3.88B | -$3.01B | -$605.7M | -$1.17B | -$1.09B | — |
| Buybacks | $500.5M | $250.0M | $250.0M | $0 | $0 | $0 | $0 | $432.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001792044-26-000013.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |